Early trial tests 'Double Antibody' to fight lupus from within

NCT ID NCT06400537

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called A-319 in people with active or treatment-resistant lupus. The drug is designed to guide the body's own T cells to find and destroy the harmful B cells that drive lupus inflammation. Researchers will check if the treatment is safe, how it behaves in the body, and if it shows signs of helping control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030032, China

Contact Email: •••••@•••••
Wuhan Union Hospital
RECRUITING

Wuhan, Hubei, 430000, China

Contact Phone: •••-•••-••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS